HomeHALO • NASDAQ
add
Halozyme Therapeutics, Inc.
Previous close
$62.65
Year range
$46.26 - $79.50
Market cap
7.37B USD
Avg Volume
2.45M
P/E ratio
18.85
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 354.26M | 22.12% |
Operating expense | 63.85M | 8.21% |
Net income | 175.22M | 27.89% |
Net profit margin | 49.46 | 4.72% |
Earnings per share | 1.72 | 35.43% |
EBITDA | 236.84M | 30.02% |
Effective tax rate | 19.97% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 701.96M | 5.35% |
Total assets | 2.22B | 4.87% |
Total liabilities | 1.72B | 3.12% |
Total equity | 503.92M | — |
Shares outstanding | 117.60M | — |
Price to book | 14.60 | — |
Return on assets | 25.49% | — |
Return on capital | 27.84% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 175.22M | 27.89% |
Cash from operations | 178.60M | 54.80% |
Cash from investing | 201.61M | 220.38% |
Cash from financing | -22.40M | -220.69% |
Net change in cash | 357.80M | 1,166.61% |
Free cash flow | 104.89M | -1.17% |
About
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
Founded
1998
Headquarters
Website
Employees
350
